MedPath

Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Drugs in Patients With Elevated Cholesterol Levels (0653A-058)

Phase 3
Completed
Conditions
Hypercholesterolemia
Registration Number
NCT00090298
Lead Sponsor
Organon and Co
Brief Summary

A 10-week study to compare the reduction in cholesterol following treatment with two different marketed drugs in patients with hypercholesterolemia.

Detailed Description

The duration of treatment is 6 weeks.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
2815
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
LDL-C lowering efficacy after 6 weeks.
Secondary Outcome Measures
NameTimeMethod
Safety;changes in TC, non-HDL-C, TG, HDL-C, Apo B, LDL-C/HCL-C ratio.
© Copyright 2025. All Rights Reserved by MedPath